Second, GLP-1 drugs have shown an incredible capacity for weight loss, but the complications and side effects, as well as the cost often make it prohibitive for long-term use
The STEP (Semaglutide Treatment Effect in People with obesity) 1 trial was a randomized, placebo-controlled trial that evaluated the efficacy of once-weekly subcutaneous (SC) semaglutide 2.4 mg plus lifestyle interventions in adults with obesity without diabetes (n = 1961)
Semaglutide is a synthetic version of a naturally occurring hormone called glucagon-like peptide-1 (GLP-1)
End of First Cycle Six full sessions in
From the air we breathe to the water we drink, environmental pollutants have become unwelcome companions in our daily lives
Ozempic (semaglutide) is supplied as a single-patient-use pen for subcutaneous injection in the following strengths: 2 mg/3 mL, delivering 0.25 mg or 0.5 mg per injection